| abstract |
The disclosure relates to modified CpG-containing immunostimulatory oligonucleotides linked by a non-nucleotide linker, including 5'-TCG1AACG1TTCG1-X-G1CTTG1CAAG1CT-5'; 5'-TCG1AACG1TTCG1-Y-TCTTG2CTGTCT-5'; 5'-CTGTCG2TTCTC-X- CTCTTG2CTGTC-5'; 5'-CTGTCG2TTCTC-X-CTCTTG2CTGC-5'; 5'-TCG1AACG1TTCG1-Y-GACAG1CTGTCT-5' as well as compositions and pharmaceutical compositions thereof. The disclosure also describes methods for generating, enhancing and modifying the immune response caused by immunostimulatory compounds used for immunotherapy applications such as, but not limited to, treatment and/or prevention of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies, and bacteria, parasitic, and viral infections in adult and pediatric human and veterinary applications. In addition, immunostimulatory oligonucleotides/immunomers of the disclosure are useful as adjuvants in combination with DNA vaccines, antibodies, allergens, proteins, antigens, chemotherapeutic agents, and antisense oligonucleotides. |